Copy Link Print Information

Monalizumab

(Synonyms: IPH2201)
5 Cited Publications
Customer Review

Based on 5 publication(s) in Google Scholar

Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

For research use only. We do not sell to patients.

  • Purity: 99.69%
  • CAS No.: 1228763-95-8
  • Molecular Weight:146.3 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Monalizumab Chemical Structure
    Monalizumab Chemical Structure
CAS No.: 1228763-95-8
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Monalizumab

More
Customer Validation & Images
Flow CytometryIn Vivo Efficacy StudyELISA
  • Flow Cytometry
  • In Vivo Efficacy Study
  • ELISA
  • Flow Cytometry
  • Flow Cytometry
  • Flow Cytometry

All Checkpoint Kinase (Chk) Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG4 kappa

  • 1/16

    Immobilized NKG2A-CD94 Heterodimer Protein, Human (HEK293, His-Flag, HY-P70713) can bind Monalizumab. The EC50 for this effect is 4.83 ng/mL.

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Nov 28;16(1):865. [Abstract]

    Customer Validation
     Healthy donor PBMCs were co-cultured with SKO-007 (J3) target cells, either untreated or treated with the indicated inhibitors for 48 h. NK cell degranulation assay was conducted at an Effector/Target (E/T) ratio of 2.5:1 in complete medium at 37 °C and 5% CO2 for 2 h. To assess the role of the NKG2A or KIR receptors, NK cells pretreated with blocking mAbs for NKG2A (Monalizumab,15 min) or IgG control were incubated with Pol I inhibitor-treated target cells.

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: Carcinogenesis. 2025 Oct 22:bgaf069. [Abstract]

    Customer Validation
     Monalizumab (MNZ) (300 μg/100 μL/mouse; i.p.; once a week for five consecutive weeks). Body weights and tumor volumes were measured twice a week from the seventh day after injection of cancer cells.

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: Carcinogenesis. 2025 Oct 22:bgaf069. [Abstract]

    Customer Validation
     Plasma perforin concentrations were determined by ELISA. The results showed that Monalizumab (MNZ) (300 μg/100 μL/mouse; i.p.; once a week for five consecutive weeks) treatment significantly increased perforin levels, which were lower in RT-R-MDA-MB-231-injected mice than in MDA-MB-231-injected mice.

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Jul 1; 12(7): e009410. [Abstract]

    Customer Validation
     Degranulation of NKG2A+ KIR− NK cells after 4 hours of co-culture with untreated or 12 hours IFNγ-pretreated WT or HLA-E KO A375 cells in the presence of 5 µg/mL IgG1 or Monalizumab (mona) mAb (n=6).

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Jul 1; 12(7): e009410. [Abstract]

    Customer Validation
     Reduction in B2M KO cell population after 24 hours of co-culture of NK cells with mixed WT:B2M KO cells (1:1) at different E:T ratios in the presence of 5 µg/mL of indicated mAbs (Monalizumab (mona), etc.).

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Jan 8;42(1):135-156.e17. [Abstract]

    Customer Validation
     Flow cytometry panels demonstrating the expression level of NKG2A⁺, PD-1⁺Tim-3⁺, Granzyme B⁺ and IFN-γ⁺ in CD8⁺ tumor infiltrating T cells co-cultured with HLA-E⁺ tumor infiltrating B cells, either treated without Monalizumab (upper panel) or with Monalizumab (100 mg/mL; 20 h) (bottom panel).

  • Monalizumab Chemical Structure
    1/16
  • Monalizumab
  • Immobilized NKG2A-CD94 Heterodimer Protein, Human (HEK293, His-Flag, HY-P70713) can bind Monalizumab. The EC50 for this effect is 4.83 ng/mL.